Press coverage about Histogenics Corporation (NASDAQ:HSGX) has been trending somewhat positive recently, according to Accern Sentiment. The research group ranks the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Histogenics Corporation earned a news impact score of 0.20 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 46.8089295027715 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Shares of Histogenics Corporation (NASDAQ:HSGX) traded down $0.04 during mid-day trading on Tuesday, hitting $1.98. 64,600 shares of the stock were exchanged, compared to its average volume of 140,305. Histogenics Corporation has a 52-week low of $1.45 and a 52-week high of $2.40.
Histogenics Corporation (NASDAQ:HSGX) last posted its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.07. research analysts anticipate that Histogenics Corporation will post -1.09 EPS for the current fiscal year.
A number of research firms have weighed in on HSGX. Zacks Investment Research lowered shares of Histogenics Corporation from a “buy” rating to a “hold” rating in a research note on Monday, October 16th. HC Wainwright reiterated a “buy” rating and issued a $3.50 price target on shares of Histogenics Corporation in a research note on Thursday, November 2nd. ValuEngine lowered shares of Histogenics Corporation from a “sell” rating to a “strong sell” rating in a research note on Monday, August 14th. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $4.00 price target on shares of Histogenics Corporation in a research note on Friday, August 11th.
WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect Histogenics Corporation (HSGX) Stock Price” was first reported by Stock Observer and is the sole property of of Stock Observer. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.thestockobserver.com/2017/11/14/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-histogenics-corporation-hsgx-stock-price.html.
About Histogenics Corporation
Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
Receive News & Ratings for Histogenics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.